Pay in 4 interest-free payments of $5.33 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Jul 17, 2025 Cutting-edge treatment approach addresses neurobehavioral symptoms in neurofibromatosis type 1 A new treatment for neurobehavioral symptoms caused by neurofibromatosis type 1, or NF1, has shown promise
These could indicate underlying issues like low blood sugar (hypoglycaemia) or an adverse reaction
Sahoo, B
Patients with a personal or family history of gallbladder disease should discuss this risk with their healthcare provider before starting therapy
When the medications reach the brain and bind to receptors in the habenula, they reduce the compulsive pull behind behaviors like overeating often described by patients as "food noise." That's one reason why GLP-1s are now being studied as potential tools for treating or preventing substance use disorders
Novo Nordisk S.p.A
US$ 20.21
US$ 29.96
US$ 23.05
